About Butyrophilin-like protein 3
Butyrophilin-like protein 3 (BTNL3) is a protein
from Homo sapiens identified by UniProt accession
Q6UXE8, 466 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Butyrophilin-like protein 3 |
| UniProt accession | Q6UXE8 |
| Gene | BTNL3 |
| Organism | Homo sapiens |
| Length | 466 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.33
- high density lipoprotein cholesterol measurement · score 0.28
- apolipoprotein A 1 measurement · score 0.28
- Barrett's esophagus · score 0.09
- esophageal adenocarcinoma · score 0.05
- neoplasm · score 0.03
- colorectal adenocarcinoma · score 0.02
- colorectal cancer · score 0.02
- breast carcinoma · score 0.02
- inflammatory bowel disease · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6UXE8-F1 | alphafold | PREDICTED | 89.48 | — |
Amino-acid sequence (466 residues)
MAFVLILVLS FYELVSGQWQ VTGPGKFVQA LVGEDAVFSC SLFPETSAEA MEVRFFRNQF HAVVHLYRDG EDWESKQMPQ YRGRTEFVKD SIAGGRVSLR LKNITPSDIG LYGCWFSSQI YDEEATWELR VAALGSLPLI SIVGYVDGGI QLLCLSSGWF PQPTAKWKGP QGQDLSSDSR ANADGYSLYD VEISIIVQEN AGSILCSIHL AEQSHEVESK VLIGETFFQP SPWRLASILL GLLCGALCGV VMGMIIVFFK SKGKIQAELD WRRKHGQAEL RDARKHAVEV TLDPETAHPK LCVSDLKTVT HRKAPQEVPH SEKRFTRKSV VASQGFQAGK HYWEVDVGQN VGWYVGVCRD DVDRGKNNVT LSPNNGYWVL RLTTEHLYFT FNPHFISLPP STPPTRVGVF LDYEGGTISF FNTNDQSLIY TLLTCQFEGL LRPYIQHAMY DEEKGTPIFI CPVSWG
Explore Butyrophilin-like protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets